AstraZeneca says Imfinzi combination reduced bladder cancer recurrence risk by 49% and death risk by 42%

AZN•2026-10-24

AstraZeneca said perioperative Imfinzi plus neoadjuvant enfortumab vedotin reduced the risk of recurrence by 49% and the risk of death by 42% in muscle-invasive bladder cancer.

AstraZeneca says Imfinzi combination reduced bladder cancer recurrence risk by 49% and death risk by 42%

1. Reported results

Related News

Zoom Communications director Herbert Raymond McMaster reports sale of $151,875 in common shares

As winter nears, heating oil emerges as hurdle for Republicans in US Senate races

XBiotech names Jan-Paul Simard co-CEO alongside Sushma Shivaswamy

Nasdaq halts trading in TWG pending news at 7:50 p.m.

Nature's Miracle 10% owner Kathleen Theresa Adair reports common share acquisitions worth $11,139.020259474